1. Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines: Potential for combination therapy
- Author
-
Yukihisa Hatakeyama, Tatsuya Nagano, Yoshikazu Kotani, Daisuke Tamura, Yoshihiro Nishimura, Kazuyuki Kobayashi, Motoko Tachihara, and Masatsugu Yamamoto
- Subjects
Cancer Research ,Guanine ,Lung Neoplasms ,Time Factors ,Combination therapy ,Pemetrexed ,Pharmacology ,Thymidylate synthase ,Inhibitory Concentration 50 ,Mice ,Glutamates ,In vivo ,Carcinoma, Non-Small-Cell Lung ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Animals ,Humans ,Anthracyclines ,Active metabolite ,Cell Proliferation ,Mice, Inbred BALB C ,biology ,Chemistry ,Cell Cycle ,Drug Synergism ,In vitro ,respiratory tract diseases ,Blot ,Oncology ,biology.protein ,Female ,Drug Screening Assays, Antitumor ,Amrubicin ,medicine.drug - Abstract
The purpose is to examine the synergistic effect of pemetrexed (PEM) and amrubicin (AMR) on the proliferation of lung cancer cell lines. In vitro, dose-dependent synergistic effects of concurrent PEM and AMRol, which is an active metabolite of AMR were observed in A549 and H460 cells. In real-time RT-qPCR analysis and western blotting, expression of the target enzymes of PEM were suppressed in cells treated with amrubicinol alone. In vivo, AMR/PEM treatment also showed synergistic antitumor activity both in A549-bearing and H520-bearing mice. PEM and AMR work synergistically to inhibit the proliferation of several different lung cancer cell lines.
- Published
- 2012